An organic compound having an excellent electron injection and transport performance is provided as a material for a low-power-consumption organic electroluminescent device. A low-power-consumption organic electroluminescent device is also provided by using the compound. The compound is a compound of general formula (1) or (2) having a substituted bipyridyl and triphenylene ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and uses the compound as constituent material of at least one of the organic layers.

##STR00001##

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT.sub.2B (5-HT.sub.2B receptor), and on the prostaglandin F2receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour. ##STR00001##

An organic compound having an excellent electron injection and transport performance is provided as a material for a low-power-consumption organic electroluminescent device. A low-power-consumption organic electroluminescent device is also provided by using the compound. The compound is a compound of general formula (1) or (2) having a substituted bipyridyl and triphenylene ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and uses the compound as constituent material of at least one of the organic layers. ##STR00001##

A process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (13) or (Z)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (15) which includes: (a) reacting compound (10) with an alkyl nitrite in the presence of an acid to form compound (11A) or reacting compound (10) with an alkyl nitrite in the presence of a base to form compound (11B); (b) reacting compound (11A) with 2-haloethanol to form compound (12A) or reacting compound (11B) with 2-haloethanol to form compound (12B); and (c) reacting compound (12A) with a base to form compound (13) or reacting compound (12B) with a base to form compound (15).

A process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (13) or (Z)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (15) which includes: (a) reacting compound (10) with an alkyl nitrite in the presence of an acid to form compound (11A) or reacting compound (10) with an alkyl nitrite in the presence of a base to form compound (11B); (b) reacting compound (11A) with 2-haloethanol to form compound (12A) or reacting compound (11B) with 2-haloethanol to form compound (12B); and (c) reacting compound (12A) with a base to form compound (13) or reacting compound (12B) with a base to form compound (15).

The present invention relates to use of a chelating compound for chromatographic separation of rare earth elements, actinides, and/or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth elements, actinides and/or s-, p- and d-block metals from a mixture of at least two metal ions. The method is characterized in that it comprises the following steps: (a) providing a mixture of at least two different metal ions chosen from rare earth metal ions, actinide ions and/or s-, p- and d-block metal ions, (b) contacting metal ions comprised in said mixture to with at least one compound of general formula (I) as defined in any one of the preceding claims to form chelates; (c) subjecting the chelates from step (b) to chromatographic separation, wherein optionally at least one separated metal chelate obtained in step (c) can be subjected to at least one further chromatographic separation in order to increase the purity of the at least one separated metal chelate; and, optionally, (d) obtaining the metal from the at least one separated metal chelate.

The present invention relates to use of a chelating compound for chromatographic separation of rare earth elements, actinides, and/or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth elements, actinides and/or s-, p- and d-block metals from a mixture of at least two metal ions. The method is characterized in that it comprises the following steps: (a) providing a mixture of at least two different metal ions chosen from rare earth metal ions, actinide ions and/or s-, p- and d-block metal ions, (b) contacting metal ions comprised in said mixture to with at least one compound of general formula (I) as defined in any one of the preceding claims to form chelates; (c) subjecting the chelates from step (b) to chromatographic separation, wherein optionally at least one separated metal chelate obtained in step (c) can be subjected to at least one further chromatographic separation in order to increase the purity of the at least one separated metal chelate; and, optionally, (d) obtaining the metal from the at least one separated metal chelate.

The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.